Agilent Technologies Inc vs iShares International Treasury Bond ETF — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while iShares International Treasury Bond ETF trades at $41.13. The key difference: Agilent Technologies Inc pays a 0.69% dividend while iShares International Treasury Bond ETF pays none, and Agilent Technologies Inc is trading nearer its 52-week high, iShares International Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| A | IGOV | |
|---|---|---|
Market Cap | $42.00B | — |
Sector | Health | — |
52-Week High | $157.20 | $43.09 |
52-Week Low | $110.24 | $40.35 |
Enterprise Value | $43.55B | — |
Dividend Yield | 0.69% | — |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
IGOV trades at $41.45, up 0.44% today, with a bullish technical signal from moving averages. The stock shows neutral oscillator readings, with the 6-day relative strength index at 71.27 indicating potential overbought conditions. Support and resistance cluster near $41-$42, suggesting tight price consolidation. Recent news highlights downside risks from global bond sell-offs affecting the ETF's duration exposure.
The outlook balances technical strength against fundamental headwinds from rising interest rates. Investment opportunity lies in trend continuation if bullish momentum holds, but risks include capital loss amplification from high duration in inflationary environments. Investors should weigh technical buy signals against macroeconomic pressures on bond ETFs.
Trailing returns across standard periods
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →